Rogue RNA Modification Hijacks Cellular Aging to Fuel Colorectal Cancer

Cellular senescence—a state of permanent growth arrest—has long been considered a tumor-suppressive mechanism, but accumulating evidence shows that senescent tumor cells (STCs) can paradoxically accelerate cancer progression. The key driver of this dark side is the senescence-associated secretory phenotype (SASP), a secreted mixture of cytokines, growth factors, and matrix-remodeling enzymes that reshape the tumor microenvironment (TME). Despite its importance, the molecular switches that program a pro-tumorigenic SASP in cancer cells remained poorly understood.

This study examined the role of N1-methyladenosine (m1A), a post-transcriptional RNA modification, in colorectal cancer (CRC). Using immunohistochemistry, dot-blot assays, and public genomics datasets, the researchers first established that m1A levels are significantly elevated in CRC tumor tissues relative to adjacent normal tissue, and that higher m1A correlates with worse overall survival in patients. The primary writer of tRNA-m1A, the TRMT6/TRMT61A methyltransferase complex, was similarly overexpressed in tumors.

Mechanistically, TRMT6/61A-mediated m1A deposition on specific tRNAs enhances the decoding efficiency of their cognate codons. This codon-biased translational boost selectively increases synthesis of ARG2 (arginase 2), a mitochondrial enzyme involved in arginine metabolism. Elevated ARG2 in turn activates both mTOR and NF-κB signaling pathways, establishing a robust SASP program. The resulting secretome promotes proliferation and invasiveness of neighboring cancer cells, activates cancer-associated fibroblasts (CAFs), and skews macrophage polarization toward an immunosuppressive M2 phenotype—collectively creating a TME highly permissive to malignancy.

The paper demonstrates a complete epitranscriptomic regulatory axis: TRMT6/61A → tRNA-m1A → codon-biased ARG2 translation → mTOR/NF-κB → SASP → TME remodeling. This represents a new layer of translational control in aging-associated cancer pathology, distinct from previously described m6A-based regulation. Importantly, each node of this axis—the methyltransferase complex, ARG2, mTOR, and NF-κB—represents a potentially druggable target, with the authors arguing for senomorphic therapies that suppress the pro-tumorigenic SASP without necessarily eliminating senescent cells.

The findings position the TRMT6/61A–ARG2 axis as a key driver of protumorigenic senescence in CRC and open avenues for biomarker development (m1A levels as a prognostic indicator) and novel therapeutic strategies targeting epitranscriptomic regulators of the SASP.